stockrow
Saturday 7 November 2026
Export KYTX’s income statement to Excel — free account
Kyverna Therapeutics, Inc.
KYTX Healthcare Biotechnology
Kyverna Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $7.0 million.
- EPS
- +35.1%
- Free cash flow
- −27.1%
- Total debt
- +95,603.8%
Quarter to June 2026, against a year earlier
4.85
0.24
+5.21%
Follow KYTX
Alert me
Kyverna Therapeutics, Inc. (KYTX) P/E ratio
Kyverna Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| FULC Fulcrum Therapeutics, Inc. compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| DTIL Precision BioSciences, Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| AGEN Agenus Inc. compare | 10.7× |
| SCTX Scribe Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)